In melanoma, a phase III study shows encouraging data following combined treatment with chemotherapy and DCs vaccination with the addition of a Cyclooxygenase-2 (COX-2) inhibitor, and in lung cancer with the addition of autologous T cells. This evidence concerns the gene PTGS2 and lung carcinoma.